Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells

Cancer Research

Volumn 64, Issue 21, 2004, Pages 8057-8061

  Karcher, Jochen ^a,b   Dyckhoff, Gerhard ^a   Beckhove, Philipp ^c   Reisser, Christoph ^a,b   Brysch, Michael ^c   Ziouta, Yvonne ^c   Helmke, Burkhard H ^a   Weidauer, Hagen ^a   Schirrmacher, Volker ^c   Herold Mende, Christel ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Caritasklinik St Theresia ^*  (Austria)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD; CANCER CELL; CANCER CELL CULTURE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DELAYED HYPERSENSITIVITY; DNA MODIFICATION; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREACTIVITY; MALE; PILOT STUDY; POSTOPERATIVE CARE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS RECOMBINATION;

ADULT; AGED; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; HYPERSENSITIVITY, DELAYED; MALE; MIDDLE AGED; NEWCASTLE DISEASE VIRUS; PILOT PROJECTS; T-LYMPHOCYTES; VACCINATION;

EID: 7444229927     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1545     Document Type: Article

References (28)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics 2002. CA Cancer J Clin 2002;52:23-47.
2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
3. Herold-Mende C, Andl T, Laemmler F, Reisser C, Eichhorn S. Expression and localization profile of tenascin in squamous cell carcinomas of the head and neck. HNO 1999;47:723-9.
4. Heimdal JH, Aarstad HJ, Klementsen B, Olofsson J. Peripheral blood mononuclear cell (PBMC) responsiveness in patients with head and neck cancer in relation to tumour stage and prognosis. Acta Otolaryngol 1999;119:281-4.
5. Tisch M, Heimlich F, Daniel V, Opelz G, Maier H. Cellular immune defect caused by postsurgical radiation therapy in patients with head and neck cancer. Otolaryngol Head Neck Surg 1998;119:412-7.
6. Qin H, Valentino J, Manna S, et al. Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression. Mol Ther 2001;4:551-8.
7. Karcher J, Reisser C, Daniel V, Herold-Mende C. Expression der immunsupprimierenden Zytokine TGF-β2 und Il-10 in Kopf-Hals-Tumoren- Vergleich von Serumwerten und Gewebeexpression. HNO 1999;47:879-84.
8. Chang AE, Li Q, Jiang G, Teknos TN, Chepeha DB, Bradford CR. Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer. Head Neck 2003;25:198-209.
9. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science (Wash D C) 1996;271:1734-6.
10. Gotte K, Usener D, Riedel F, Hormann K, Schadendorf D, Eichmuller S. Tumor-associated antigens as possible targets for immune therapy in head and neck cancer: comparative mRNA expression analysis of RAGE and GAGE genes. Acta Otolaryngol 2002;122:546-52.
11. Bier H, Armonat G, Schirrmacher V, Ganzer U. Postoperative active-specific immunotherapy of lymph node micrometastasis in a guinea pig tumor model. ORL J Otorhinolaryngol Relat Spec 1989;51:197-205.
12. Matzinger P. The danger model: a renewed sense of self. Science (Wash D C) 2002;296:301-5.
13. Nelson NJ. Scientific interest in Newcastle Disease Virus is reviving. J Natl Cancer Inst (Bethesda) 1999;91:1708-10.
14. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R, Ertel C. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle Disease Virus. Gene Ther 1999;6:63-73.
15. Termeer CC, Schirrmacher V, Broecker EB, Becker JC. Newcastle-Disease- Virus infection induces a B7-1/ B7-2 independent T-cell-costimulatory activity in human melanoma cells. Cancer Gene Ther 2000;7:316-23.
16. Washburn B, Schirrmacher V. Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int J Oncol 2002;21:85-93.
17. Schirrmacher V, Ahlert T, Proebstle T, et al. Immunization with virus-modified tumor cells. Semin Oncol 1998;25:677-96.
18. Ninck S, Reisser C, Dyckhoff G, Helmke B, Bauer H, Herold-Mende C. Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer 2003;106:34-44.
19. Feuerer M, Beckhove P, Bai L, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001;7:452-8.
20. Herold-Mende C, Steiner HH, Andl T, et al. Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab Investig 1999;79:1573-82.
21. Young MR, Lathers DM. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int J Immunopharmacol 1999;21:241-52.
22. Thomas GR, Chen Z, Enamorado I, Bancroft C, Van Waes C. IL-12- and IL-2-induced tumor regression in a new murine model of oral squamous-cell carcinoma is promoted by expression of the CD80 co-stimulatory molecule and interferon-gamma. Int J Cancer 2000;86:368-74.
23. Ahlert T, Sauerbrei W, Bastert G, et al. Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J Clin Oncol 1997;15:1354-66.
24. Naujocks G, Serwe M, Bayer TA, Schirrmacher V. Adoptive transfer via immune T-lymphocytes of effective anti-tumor immunity against a malignant rat glioma in the brain. Int J Oncol 1997;11:249-54.
25. Schlag P, Manasterski M, Gerneth T, et al. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother 1992;35:325-30.
26. Von Hoegen P, Zawatzky R, Schirrmacher V. Modification of tumor cells by a low dose of Newcastle Disease Virus: III. Potentiation of tumor specific cytolytic T-cell activity via induction of interferon, alfa, beta. Cell Immunol 1990;126:80-90.
27. Gleich LL, Collins CM, Gartside PS, et al. Therapeutic decision making in stages III and IV head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2003;129:26-35.
28. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55.